Charles River Laboratories International Inc Dossier
|
SectorHealth Care IndustryDiagnostics & Research Beta (adjusted)1.25 Intrinsic Value $209.28median of 3 methodsbased on filings through 27 Jun 2026 Market Price $286.83Price as of 1 Oct 2026 OvervaluedIntrinsic value is 27% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $13.8B Enterprise Value $15.7B Shares Outstanding 48M diluted Moat Rating None Next Earnings Date4 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Charles River's second-quarter 2026 results provide credible evidence of an early operating inflection: organic revenue increased 0.1%, DSA returned to 0.2% organic growth, companywide non-GAAP operating margin rose 420 basis points sequentially to 20.5%, and 2026 organic-revenue and non-GAAP EPS guidance were raised. The recovery is nevertheless immature. Reported revenue declined 2.7%, RMS organic revenue fell 1.4%, companywide non-GAAP margin remained below the prior-year quarter, and full-year organic-growth guidance is only 0.0%-1.0%. Completed divestitures sharpen the regulated-testing focus but also complicate comparisons and generated a material GAAP loss adjustment. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$145.00 Mean target$281.00 High · most bullish analyst$318.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $145.0019% The DSA improvement proves temporary, RMS contraction persists, and organic revenue falls below guidance. Higher study-related direct costs and corporate overhead prevent durable margin expansion, while restructuring and divestiture adjustments continue to obscure underlying earnings quality. Base CaseCentral scenario $281.0057% Matches the consensus meanThe company delivers within its 0.0%-1.0% organic-revenue and $11.15-$11.45 non-GAAP EPS guidance ranges. DSA improves gradually, Manufacturing remains constructive, and RMS continues to constrain growth. Portfolio simplification and efficiency measures support earnings, but modest underlying growth and the gap between GAAP and adjusted results limit conviction. Bull CaseUpside scenario $318.0024% Improving biopharmaceutical demand translates into sustained DSA growth, organic revenue finishes at or above the upper end of the 2026 range, and efficiency initiatives preserve the strong sequential margin recovery. Manufacturing remains resilient after portfolio simplification, while digital pathology and AI-enabled collaborations improve client relevance and productivity. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |